Biological Safety Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

Biological Safety Testing Market Trends and Forecast

The future of the global biological safety testing market looks promising with opportunities in the vaccine & therapeutic, cellular & gene therapy, and blood & blood-based therapy markets. The global biological safety testing market is expected to grow with a CAGR of 13.2% from 2025 to 2031. The major drivers for this market are the increasing production of biopharmaceutical products, the rising concerns about product contamination risks, and the growing investment in advanced biosafety testing.

• Lucintel forecasts that, within the product type category, reagent & kit is expected to witness higher growth over the forecast period.

• Within the application category, cellular & gene therapy is expected to witness the highest growth.

• In terms of region, APAC is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Biological Safety Testing Market

Emerging trends in biological safety testing market harness rapid detection, ethical alternatives, and automation to tackle contamination risks in complex biologics. Innovations streamline workflows, cut timelines, and align with sustainability demands globally.

• Rapid Microbial Methods: RMMs like accelerated sterility deliver results swiftly without compromising accuracy. Impacts expedite releases for vaccines and injectables, slashing delays and costs while meeting pharmacopeial standards in high-volume manufacturing.

• Animal-Free Endotoxin Tests: Recombinant Factor C cartridges replace horseshoe crabs ethically. Revolutionizes sustainability, ensures supply reliability, and fulfills regulations for gene therapies amid ethical pressures.

• Automation Robotics Surge: Robotic systems automate aliquoting and incubation precisely. Boosts throughput for CGT, minimizes errors, and frees experts for complex analyses in scaling biopharma pipelines.

• Outsourcing CRO Boom: Pharma delegates to specialists like Charles River for expertise. Accelerates timelines, leverages global networks, and optimizes costs for emerging modalities.

• CGT Safety Focus: Tailored assays for viral clearance and adventitious agents. Enables safe commercialization, builds confidence, and unlocks regenerative therapy potentials rapidly. These trends transform testing into agile, eco-friendly ecosystems, diminishing bottlenecks and ethical hurdles. Market evolves toward predictive, integrated platforms redefining biologic integrity worldwide.

Recent Development in the Biological Safety Testing Market

Pivotal developments in biological safety testing market, spotlight launches and expansions fortifying rapid, compliant testing infrastructures amid therapy surges.

• Rapid Sterility Launch: Nelson Labs deploys six-day sterility confirmation across sites. Speeds device and pharma releases, upholds USP compliance, and revolutionizes supply chains.

• Animal-Free Cartridge: Charles River‘s Trillium rCR enables robust endotoxin detection sans animals. Promotes sustainability, secures supplies, and aligns with global ethical mandates.

• Shanghai Biosafety Labs: Merck KGaA establishes facility for lot release testing. Localizes services, accelerates Asia timelines, and supports regional biotech growth.

• CHO Stability Assay: Merck‘s Aptegra cuts genetic testing durations significantly. Streamlines cell line validations, reduces expenses, and fast-tracks therapeutic developments.

• Bionique Lab Expansion: New spaces enhance mycoplasma and viral capabilities. Meets CGT demands, bolsters rapid biosafety, and scales drug pipelines effectively. These innovations catalyze efficiency gains, ethical advancements, and capacity builds, embedding resilient testing as biologics cornerstone.

Strategic Growth Opportunities in the Biological Safety Testing Market

The biological safety testing market growth targets modality expansions, leveraging innovations for vaccines, therapies, and emerging biologics.

• Gene Therapy Viral Safety: Adventitious agent assays ensure clearance rigorously. Accelerates approvals, mitigates risks, and propels curative pipelines forward.

• Cell Therapy Sterility: Rapid methods validate viability and purity swiftly. Unlocks scalable manufacturing, enhances safety, and broadens regenerative accesses.

• Vaccine Endotoxin Control: Animal-free kits safeguard injectables efficiently. Boosts production speeds, meets demands, and fortifies immunization campaigns.

• mAb Bioburden Testing: Automation handles volumes for biosimilars seamlessly. Supports affordability, regulatory paths, and market expansions dynamically.

• Blood Products Authentication: Cell line and mycoplasma checks secure transfusions. Improves donor safety, complies standards, and sustains supplies reliably. Modality-focused surges diversify revenues, amplify capacities, and pioneer compliant innovations, positioning testing as biopharma enabler globally.

Biological Safety Testing Market Driver and Challenges

Major drivers and challenges in biological safety testing market involve regulatory mandates, therapy booms, outsourcing efficiencies, tech shifts, countered by costs, ethics, and complexities. The factors responsible for driving the biological safety testing market include: 1. Biologics Approvals Rise: Surging mAbs and biosimilars demand rigorous validations. Fuels service volumes, investments, and specialized infrastructures robustly. 2. CGT ATMP Expansion: Cell-gene therapies require advanced contamination checks. Propels tailored assays, R&D, and facility upgrades dynamically. 3. Stringent Regulations Enforce: FDA EMA guidelines mandate comprehensive testing. Drives compliance tools, outsourcing, and quality elevations consistently. 4. R&D Investments Surge: Pharma funds novel safety innovations aggressively. Accelerates rapid methods, animal-free shifts, and global collaborations. 5. Contamination Risk Awareness: Culture vulnerabilities heighten preventive testing needs. Boosts bioburden and sterility adoptions proactively. Challenges in the biological safety testing market are: 1. High Testing Costs Persist: Complex assays strain budgets persistently. Limits access, spurs efficiencies, and innovation necessities. 2. Animal Testing Ethics: LAL dependencies face welfare scrutiny. Mandates alternatives, regulatory pivots, and supply diversifications urgently. 3. Biologic Heterogeneity Challenges: Variability complicates standardization efforts. Demands advanced analytics, validations, and expertise builds. Drivers decisively outpace challenges, igniting rapid, ethical evolutions. Testing solidifies as agile pillar, unlocking biologic potentials sustainably.

List of Biological Safety Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biological safety testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biological safety testing companies profiled in this report include-

• Avance Biosciences

• Cytovance Biologics

• Eurofins Scientific

• Lonza

• Merck

• Promega Corporation

• Thermo Fisher Scientific

• Toxikon

• WuXi AppTec

• Biomerieux

Biological Safety Testing Market by Segment

The study includes a forecast for the global biological safety testing market by product type, test, application, and region.

Biological Safety Testing Market by Product Type [Value from 2019 to 2031]:

• Reagents & Kits

• Instruments

• Others

Biological Safety Testing Market by Test [Value from 2019 to 2031]:

• Sterility Tests

• Bioburden Tests

• Endotoxin Tests

• Others

Biological Safety Testing Market by Application [Value from 2019 to 2031]:

• Vaccines & Therapeutics

• Cellular & Gene Therapy

• Blood & Blood-Based Therapy

• Others

Biological Safety Testing Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Biological Safety Testing Market

The biological safety testing market surges with rapid microbial methods, animal-free innovations, and facility expansions amid biologics and cell-gene therapy booms. Regulatory simplifications and strategic investments enhance compliance, speed, and global supply chains across key regions.

• United States: United States leads via FDA guidance streamlining biosimilar testing, reducing clinical burdens. Nelson Labs launches rapid sterility confirming results swiftly, while Bionique expands for mycoplasma and viral assays, bolstering gene therapy support and accelerating product releases nationwide.

• China: China advances through WuXi Biologics‘ manufacturing expansions incorporating biosafety labs and Merck KGaA‘s Shanghai facility for cell characterization. Local testing capabilities strengthen supply chains, supporting domestic biologics production and international partnerships efficiently.

• Germany: Germany excels with Eurofins‘ ethylene oxide sterilization expansions and Merck‘s Aptegra CHO assay slashing genetic stability times. Precision tools elevate compliance for advanced therapies, positioning the nation as Europe‘s R&D hub for rigorous safety validations.

• India: India propels via Biocon‘s Humira biosimilar launch demanding robust testing. Government funding fuels lab networks for vaccines and cell therapies, bridging cost gaps and enabling scalable, affordable safety assessments in emerging biotech corridors.

• Japan: Japan prioritizes regenerative medicine with government-backed biopharma expansions. Enhanced endotoxin and mycoplasma testing supports stem cell approvals, aligning infrastructure with aging demographics for reliable, high-quality biologic safeguards.

Features of the Global Biological Safety Testing Market

Market Size Estimates: Biological safety testing market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Biological safety testing market size by product type, test, application, and region in terms of value ($B). Regional Analysis: Biological safety testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different product types, tests, applications, and regions for the biological safety testing market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biological safety testing market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for biological safety testing market? Answer: The global biological safety testing market is expected to grow with a CAGR of 13.2% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the biological safety testing market? Answer: The major drivers for this market are the increasing production of biopharmaceutical products, the rising concerns about product contamination risks, and the growing investment in advanced biosafety testing. Q3. What are the major segments for biological safety testing market? Answer: The future of the biological safety testing market looks promising with opportunities in the vaccine & therapeutic, cellular & gene therapy, and blood & blood-based therapy markets. Q4. Who are the key biological safety testing market companies? Answer: Some of the key biological safety testing companies are as follows:

• Avance Biosciences

• Cytovance Biologics

• Eurofins Scientific

• Lonza

• Merck

• Promega Corporation

• Thermo Fisher Scientific

• Toxikon

• WuXi AppTec

• Biomerieux Q5. Which biological safety testing market segment will be the largest in future? Answer: Lucintel forecasts that, within the product type category, reagent & kit is expected to witness higher growth over the forecast period. Q6. In biological safety testing market, which region is expected to be the largest in next 5 years? Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.